Prospective pharmaceuticals process

In most cases, ointments, suppositories, ophthalmic, and parenteral products assume the color of their ingredients and do not contain color additives. In addition to esthetics and the certification status of a dye, a formulation pharmacist must select the dyes to be used in a particular formula on the basis of the physical and chemical properties of the dyes available. Of prime importance is the solubility of a prospective dye in the vehicle to be used for a liquid formulation or in a solvent to be employed during a pharmaceutical process (such as when the dye is sprayed on a batch of tablets). In general, most dyes are broadly grouped into those that are water-soluble and those that are oil-soluble few, if any, dyes are both. 

J.K. Liang, S. Byrn, A. Newman, J. Stults and V. Smolenskayay, On-line Raman spectroscopy in pharmaceutical process development Application and future prospects. Am. Pharm. Rev., 10, 45-51 (2007). 

Inorganic NO donors are good examples of prospective pharmaceuticals activated via their photodissociation, photosubstitution, and photoredox processes. 

Chao AY, Forbes ES, Johnson RE, von Doehren P. Prospective process validation. In Loftus BT, Nash RA, eds. Pharmaceutical Process Validation. New York Marcel Dekker, 1984 125—148. 

ACS ProSpectives Conference Process Chemistry in the Pharmaceutical Industry, Barcelona, Spain, February 24-27, 2002 14th International Symposium on Chirality, Hamburg, Germany, September 8-12, 2002. 

What is less clear is how, or whether, the roles of pharmacists will grow or advance. Since no significant increase in the number of practicing pharmacists can be foreseen in the immediate future to take on this increasing workload, while hopefully continuing to expand services and the delivery of pharmaceutical care, pharmacy clearly faces a major challenge. More use of better trained, certified, or even licensed technicians is one approach. More automation and computerization is another. A rapid growth in the expected use of electronic prescriptions may also allow further efficiencies—even the prospect of a paperless automated process. 

Proving or demonstrating that the process works Prospective, concurrent, retrospective, revalidation Chemical, pharmaceutical, automation, cleaning Flow diagram, equipment/components, in-process, finished product... 

Raman spectroscopy has developed rapidly in the past few years and there are very interesting prospects for future process applications. By building on the fact that Raman spectroscopy is fast, selective, informative and can be remotely coupled to process vessels, it is very likely that we will see Raman spectrometers much more widely used in pharmaceutical manufacturing. Several challenges are still hampering future success in some areas as discussed above. In particular, more efforts on interfacing the Raman spectrometer to different secondary process unit operations are needed before we will see the robust use of the technique. 

Yet, as explained in the preceding chapter [1], the immediate prospects for the pharmaceutical industry are fairly bleak While the expenditures for research and development continue to rise almost exponentially, the outcome in terms of new successful drugs has shown a clear tendency to decline, and today the development costs for a single dmg can easily run into the one billion Euro bracket Moreover, two out of three drugs fail in the last phase of the development process, at a stage where enormous investments in time and money have already been made. 

If one asks the question, What is my computer supposed to be doing when I m providing pharmaceutical care the answer will not only describe the appropriate hardware or device that matches the needs of the professional providing the care, but should also describe the optimal software that will support the provision of pharmaceutical care. We define the point-of-care as the place where a pharmacist provides pharmaceutical care to a patient or assists a colleague (pharmacist, physician, or nurse) in the provision of care. Many kinds of software available on the market today focus solely on transaction processing, with minimal decision support available through prospective drug utilization review (DUR) modules. 

---